Circulatory neurosteroid levels in smoking and non-smoking chronic schizophrenia patients

European Neuropsychopharmacology

Volumn 17, Issue 8, 2007, Pages 541-545

  Iancu, Iulian ^a,b   Tchernihovsky, Eleonora ^a,b   Maayan, Rachel ^b   Poreh, Amir ^c   Dannon, Pinhas ^a,b   Kotler, Moshe ^a,b   Weizman, Abraham ^b,d   Strous, Rael D ^a,b  

^a BEER YAAKOV MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c CLEVELAND STATE UNIVERSITY   (United States)

^d GEHA MENTAL HEALTH CENTER   (Israel)

Author keywords

Addiction; Neurosteroids; Nicotine; PANSS; Schizophrenia; Smoking

Indexed keywords

HYDROCORTISONE; NEUROSTEROID; PRASTERONE; PRASTERONE SULFATE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; MENTAL PATIENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING; STEROID BLOOD LEVEL;

ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; HUMANS; HYDROCORTISONE; MALE; NEUROTRANSMITTER AGENTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SMOKING; STEROIDS;

EID: 34248592529     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.02.001     Document Type: Article

References (25)

1. Akwa Y., and Baulieu E.E. Dehydroepiandrosterone sulfate and dehydro-epiandrosterone: neuroactive neurosteroids. Curr. Opin. Endocrinol. Diabetes 7 (2000) 160-167
2. Bjornerem A., Straume B., Midtby M., Fonnebo V., Sundsfjord J., Svartberg J., Acharya G., Oian P., and Berntsen G.K. Endogenous sex hormones in relation to age, sex, lifestyle factors, and chronic diseases in a general population: the Tromso Study. J. Clin. Endocrinol. Metab. 89 (2004) 6039-6047
3. Dalack G.W., Healy D.J., and Meador-Woodruff J.H. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am. J. Psychiatr. 155 (1998) 1490-1501
4. Doron R., Fridman L., Gispan-Herman I., Maayan R., Weizman A., and Yadid G. DHEA, a neurosteroid, decreases cocaine self-administration and reinstatement of cocaine-seeking behavior in rats. Neuropsychopharmacology 31 10 (2006) 2231-2236 (Jan 18)
5. Feldman H.A., Johannes C.B., McKinlay J.B., and Longcope C. Low dehydroepiandrosterone sulfate and heart disease in middle-aged men: cross-sectional results from the Massachusetts Male Aging Study. Ann. Epidemiol. 8 (1998) 217-228
6. Field A.E., Colditz G.A., Willett W.C., Longcope C., and McKinlay J.B. The relation of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormones, and sex hormone-binding globulin in middle-aged men. J. Clin. Endocrinol. Metab. 79 (1994) 1310-1316
7. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P) (2002), Biometrics Research, New York State Psychiatric Institute, New York
8. Hautanen A., Manttari M., Kupari M., Sarna S., Manninen V., Frick M.H., and Adlercreutz H. Cigarette smoking is associated with elevated adrenal androgen response to adrenocorticotropin. J. Steroid Biochem. Mol. Biol. 46 (1993) 245-251
9. Johnson M.D., Bebb R.A., and Sirrs S.M. Uses of DHEA in aging and other disease states. Ageing Res. Rev. 1 (2002) 29-41
10. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
11. Maayan R., Lotan S., Doron R., Shabat-Simon M., Gispan-Herman I., Weizman A., and Yadid G. Dehydroepiandrosterone (DHEA) attenuates cocaine-seeking behavior in the self-administration model in rats. Eur. Neuropsychopharmacol. 16 (2006) 329-339
12. Majewska M.D. Neurosteroids: endogenous bimodal modulators of the GABA-A receptor. Mechanism of action and physiological significance. Prog. Neurobiol. 38 (1992) 379-395
13. Marx C.E., Trost W.T., Shampine L., Behm F.M., Giordano L.A., Massing M.W., and Rose J.E. Neuroactive steroids, negative affect, and nicotine dependence severity in male smokers. Psychopharmacology (Berlin) 186 (2006) 462-472
14. Newcomer J.W., Faustman W.O., Whiteford H.A., Moses Jr., J.A., and Csernansky J.G. Symptomatology and cognitive impairment associate independently with post-dexamethasone cortisol concentrations in unmedicated schizophrenic patients. Biol. Psychiatry 29 (1991) 855-864
15. Oncken C., Prestwood K., Cooney J.L., Unson C., Fall P., Kulldorff M., and Raisz L.G. Effects of smoking cessation or reduction on hormone profiles and bone turnover in postmenopausal women. Nicotine Tob. Res. 4 (2002) 451-458
16. Porcu P., Sogliano C., Cinus M., Purdy R.H., Biggio G., and Concas A. Nicotine-induced changes in cerebrocortical neuroactive steroids and plasma corticosterone concentrations in the rat. Pharmacol. Biochem. Behav. 74 (2003) 683-690
17. Ritsner M., Maayan R., Gibel A., Strous R.D., Modai I., and Weizman A. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. Eur. Neuropsychopharmacol. 14 (2004) 267-273
18. Ritsner M., Gibel A., Maayan R., Ratner Y., Ram E., Biadsy H., Modai I., and Weizman A. Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia. Neuropsychopharmacology 30 (2005) 1913-1922
19. Salvini S., Stampfer M.J., Barbieri R.L., and Hennekens C.H. Effects of age, smoking and vitamins on plasma DHEAS levels: a cross-sectional study in men. J. Clin. Endocrinol. Metab. 74 (1992) 139-143
20. Shirayama Y., Hashimoto K., Suzuki Y., and Higuchi T. Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia. Schizophr. Res. 58 (2002) 69-74
21. Strous R.D., Maayan R., Lapidus R., Stryjer R., Lustig M., Kotler M., and Weizman A. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch. Gen. Psychiatry 60 (2003) 133-141
22. Strous R.D., Maayan R., Lapidus R., Goredetsky L., Zeldich E., Kotler M., and Weizman A. Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology. Schizophr. Res. 71 (2004) 427-434
23. Tandon R., DeQuardo J.R., Taylor S.F., McGrath M., Jibson M., Eiser A., and Goldman M. Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr. Res. 45 (2000) 191-201
24. Weiser M., Reichenberg A., Grotto I., Yasvitzky R., Rabinowitz J., Lubin G., Nahon D., Knobler H.Y., and Davidson M. Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. Am. J. Psychiatr. 161 (2004) 1219-1223
25. Wen S., Dong K., Onolfo J.P., and Vincens M. Treatment with dehydroepiandrosterone sulfate increases NMDA receptors in hippocampus and cortex. Eur. J. Pharmacol. 430 (2001) 373-374